MA52090A - Polythérapie - Google Patents

Polythérapie

Info

Publication number
MA52090A
MA52090A MA052090A MA52090A MA52090A MA 52090 A MA52090 A MA 52090A MA 052090 A MA052090 A MA 052090A MA 52090 A MA52090 A MA 52090A MA 52090 A MA52090 A MA 52090A
Authority
MA
Morocco
Prior art keywords
polytherapy
Prior art date
Application number
MA052090A
Other languages
English (en)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MA52090A publication Critical patent/MA52090A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052090A 2018-03-21 2019-03-20 Polythérapie MA52090A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862646314P 2018-03-21 2018-03-21

Publications (1)

Publication Number Publication Date
MA52090A true MA52090A (fr) 2021-04-21

Family

ID=67988025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052090A MA52090A (fr) 2018-03-21 2019-03-20 Polythérapie

Country Status (16)

Country Link
US (1) US20210000838A1 (fr)
EP (1) EP3768258A4 (fr)
JP (1) JP2021517116A (fr)
KR (1) KR20200135439A (fr)
CN (1) CN112165939A (fr)
AU (1) AU2019238207A1 (fr)
BR (1) BR112020019082A2 (fr)
CA (1) CA3093847A1 (fr)
EA (1) EA202092154A1 (fr)
IL (1) IL277336A (fr)
MA (1) MA52090A (fr)
MX (1) MX2020009773A (fr)
SG (1) SG11202009137PA (fr)
TW (1) TW202002983A (fr)
WO (1) WO2019183226A1 (fr)
ZA (1) ZA202005661B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691384B1 (fr) 2011-03-28 2016-10-26 MEI Pharma, Inc. (aralkylamino- et heteroaralkylamino)-pyrimidinyl- et 1,3,5-triazinyl-benzimidazoles substitues sur la position alpha, compositions pharmaceutiques les contenant et ces composes destines a etre utilises dans le traitement des maladies proliferatives
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
EP4509183A3 (fr) 2016-08-16 2025-05-21 BeiGene Switzerland GmbH Forme cristalline du (s)-7-(1-acryloylpipéridin-4-yl)-2-(4-phénoxyphényl)-4,5,6,7-tétra-hydropyrazolo[1,5-a!pyrimidine-3-carboxamide, préparation et utilisations associées
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
CA3063976A1 (fr) 2017-05-23 2018-11-29 Mei Pharma, Inc. Polytherapie
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
WO2019036489A1 (fr) 2017-08-14 2019-02-21 Mei Pharma, Inc. Polythérapie
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2020249001A1 (fr) * 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 Comprimé solide pour voie orale comprenant un inhibiteur de tyrosine kinase de bruton et son procédé de préparation
CN113950327A (zh) * 2019-06-10 2022-01-18 百济神州瑞士有限责任公司 口服胶囊剂及其制备方法
CN110922409A (zh) * 2019-12-19 2020-03-27 武汉九州钰民医药科技有限公司 制备btk抑制剂泽布替尼的方法
KR20210115375A (ko) * 2020-03-12 2021-09-27 보령제약 주식회사 Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691384B1 (fr) * 2011-03-28 2016-10-26 MEI Pharma, Inc. (aralkylamino- et heteroaralkylamino)-pyrimidinyl- et 1,3,5-triazinyl-benzimidazoles substitues sur la position alpha, compositions pharmaceutiques les contenant et ces composes destines a etre utilises dans le traitement des maladies proliferatives
AU2014251028A1 (en) * 2013-04-08 2015-11-05 Janssen Pharmaceutica Nv Ibrutinib combination therapy
EA201691169A1 (ru) * 2013-12-05 2016-09-30 Асерта Фарма Б.В. Терапевтическая комбинация ингибитора pi3k и ингибитора btk
TW201613644A (en) * 2014-06-17 2016-04-16 Acerta Pharma Bv Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
TW201618774A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法

Also Published As

Publication number Publication date
MX2020009773A (es) 2020-10-08
US20210000838A1 (en) 2021-01-07
JP2021517116A (ja) 2021-07-15
CN112165939A (zh) 2021-01-01
BR112020019082A2 (pt) 2020-12-29
SG11202009137PA (en) 2020-10-29
AU2019238207A1 (en) 2020-10-01
WO2019183226A1 (fr) 2019-09-26
EP3768258A1 (fr) 2021-01-27
EP3768258A4 (fr) 2022-01-12
IL277336A (en) 2020-10-29
CA3093847A1 (fr) 2019-09-26
EA202092154A1 (ru) 2021-03-22
KR20200135439A (ko) 2020-12-02
ZA202005661B (en) 2023-05-31
TW202002983A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
FIC20253006I1 (fi) Linvoseltamabi
FIC20260010I1 (fi) imlunestrantti
EP3890716A4 (fr) Polythérapies
EP3801265B1 (fr) Débitmètre urinaire
EP3846674C0 (fr) Spéculum vaginal
EP3555124C0 (fr) Tcr nyeso
EP3849534A4 (fr) Polythérapies
EP3781060A4 (fr) Cryosonde
MA47676A (fr) Polythérapie
MA46285A (fr) Polythérapie
EP3784463A4 (fr) Fluorosulfones
EP3872558A4 (fr) Optoisolateur
MA49921A (fr) Polythérapie
EP3810860C0 (fr) Coupleur
EP3792200A4 (fr) Conteneur-citerne
EP3745904C0 (fr) Poignée de bâton
EP3878374A4 (fr) Dispositif d'occlusion
EP3721129C0 (fr) Cryosphère
EP3738793A4 (fr) Pneumatique
EP3844177A4 (fr) Polythérapies
DK3587968T3 (da) Fluidsystem
MA56057A (fr) Polythérapie
EP3773733C0 (fr) Métallo-liothyronine
DK3752258T3 (da) Trampolin
EP3787554A4 (fr) Endoprothèse-greffe